The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Lupin Ltd

Lupin Ltd

BSE 500257 · NSE LUPIN · ISIN INE326A01037 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹2,164.60

-1.21%

BSE close, 28 August 2026

Market cap

₹98,973.07 cr

45.7 cr shares · Mid cap

Free float

₹52,406.44 cr

as published

P/E · P/B

14.2× · 4.50×

EPS ₹152.07 · BV ₹481.02

FY25-26 rev / PAT

19,512.66 / 6,366.56

₹ cr, as filed

Filings, window

31

15 selected · 48%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹1,881.80 52-WK HIGH ₹2,530.00 ₹2,164.60 44% of range
Against 52-week high-14.4%
Against 52-week low+15.0%
Day change-1.21%
Size bandMid cap
Index membershipNIFTY 500

Valuation as published by BSE

Earnings per share₹152.07
Price / earnings14.23×
Price / book4.50×
Book value — derived, price ÷ P/B₹481.02
Return on equity31.64%
Operating margin53.48%
Net margin37.85%

Consistency check

P/B ÷ P/E, which must equal ROE
31.62%
ROE as published
31.64%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 7,171.90 2,714.60 59.37 53.48% 37.85%
Mar-26 · Q 5,234.60 2,163.69 47.35 53.84% 41.33%
FY25-26 19,512.66 6,366.56 139.38 43.68% 32.63%

Quarter on quarter

Revenue, quarter on quarter
+37.0%
Net profit, quarter on quarter
+25.5%
Operating margin, quarter on quarter
-36 bps

Disclosure profile 31 filings in the window

0 median 17.0 p75 · 25 sector max 52 31 89th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Press Release9
Investor Presentation2
Board Outcome1
Concall Transcript1
KMP1
Results1
Selected sub-total15
Procedural
Analyst / Investor Meet4
General4
AGM / EGM2
ESOP Allotment2
Board Meeting1
Compliance Certificate1
Subsidiary Incorporation1
Trading Window1
Procedural sub-total16
Total31

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

31 filings · 15 selected · busiest 2026-08-06

Filing rhythm · the twelve most recent

2026-08-242026-10-09

SelectedProcedural

Filings

31 in the window · 23 earlier on record

  1. 9 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 8 October 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP

    Company Update / Press Release / Media Release View filing →

  3. 6 October 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Launches Formoflo-G MDI, World's First Fixed-dose Triple Combination Drug for COPD Management.

    Company Update / Press Release / Media Release View filing →

  4. 1 October 2026 ·

    General

    Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines, Inc.

    Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed buyback of 30,559 shares, pursuant to which MPPI has become a step-down wholly owned subsidiary of the Company effective ....

    Company Update / General View filing →

  5. 28 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation of Closure of Trading Window.

    Insider Trading / SAST / Closure of Trading Window View filing →

  6. 28 September 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension.

    Company Update / Press Release / Media Release View filing →

  7. 21 September 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Intimation of allotment of 24,111 equity shares under ESOP.

    Company Update / Allotment of ESOP / ESPS View filing →

  8. 8 September 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation about participating in the Analyst/Institutional Investors Meet.

    Company Update / Analyst / Investor Meet View filing →

  9. 4 September 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP.

    Company Update / Press Release / Media Release View filing →

  10. 28 August 2026 ·

    General

    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating

    ESG Rating by Crisil ESG Ratings & Analytics Ltd.

    Company Update / General View filing →

  11. 25 August 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Intimation of allotment of 30967 equity shares under ESOP.

    Company Update / Allotment of ESOP / ESPS View filing →

  12. 24 August 2026 ·

    General

    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

    ESG Rating by ESG Risk Assessment and Insights Limited.

    Company Update / General View filing →

  13. 20 August 2026 ·

    General

    Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A.

    VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.

    Company Update / General View filing →

  14. 18 August 2026 ·

    KMP

    Demise

    Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.

    Company Update / Demise View filing →

  15. 17 August 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.

    Company Update / Press Release / Media Release View filing →

  16. 12 August 2026 ·

    Concall Transcript

    Earnings Call Transcript

    Transcript of Q1 FY2027 Earnings Conference Call

    Company Update / Earnings Call Transcript View filing →

  17. 10 August 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.

    Company Update / Press Release / Media Release View filing →

  18. 10 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation about participating in the Analyst/Institutional Investors Meet.

    Company Update / Analyst / Investor Meet View filing →

  19. 7 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Link of Audio recording of the Earnings Call-Q1 FY27.

    Company Update / Analyst / Investor Meet View filing →

  20. 7 August 2026 ·

    Investor Presentation

    Investor Presentation

    Investor Presentation (Revised) - Q1 FY27 Results

    Company Update / Investor Presentation View filing →

  21. 6 August 2026 ·

    Investor Presentation

    Investor Presentation

    Investor Presentation- Q1 FY2027

    Company Update / Investor Presentation View filing →

  22. 6 August 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Q1 FY2027 Results

    Company Update / Press Release / Media Release View filing →

  23. 6 August 2026 ·

    Results

    Board Meeting Outcome For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

    Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

    Result / Financial Results View filing →

  24. 6 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

    Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

    Board Meeting / Outcome of Board Meeting View filing →

  25. 4 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Details of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizer's Report.

    AGM/EGM / AGM View filing →

  26. 4 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026.

    AGM/EGM / AGM View filing →

  27. 31 July 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Announces the approval of Diazepam Injection, USP in the United States.

    Company Update / Press Release / Media Release View filing →

  28. 31 July 2026 ·

    Press Release

    Press Release / Media Release

    Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.

    Company Update / Press Release / Media Release View filing →

  29. 22 July 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Schedule of Earnings Call for Q1 FY27

    Company Update / Analyst / Investor Meet View filing →

  30. 22 July 2026 ·

    Board Meeting

    Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

    Lupin Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....

    Board Meeting / Board Meeting View filing →

  31. 21 July 2026 ·

    Subsidiary Incorporation

    Acquisition

    Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332,000 Common Shares of Kaveri Therapeutics, Inc. U.S.A.

    Company Update / Acquisition View filing →

RSS feed for Lupin Ltd · the 50 most recent filings